May 20 (Reuters) - Advisers to the U.S. Food and Drug Administration will discuss whether to recommend COVID-19 vaccines for 2025-26 for targetting the LP.8.1 subvariant, documents filed on Tuesday showed.
The panel of advisers will make recommendations on the selection of the 2025-2026 formula for COVID-19 vaccines for use in the United States on Thursday.
(Reporting by Puyaan Singh and Christy Santhosh in Bengaluru; Editing by Anil D'Silva)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.